Skip to main content

Table 2 Associations between clinicopathologic factors and density of CD8(+) T cells and programmed cell death-1 (PD-1) expression on CD8(+) T cells in primary tumors and lymph nodes of gastric adenocarcinoma

From: Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma

Variable

Total (cases)

Density of CD8(+) T cells in primary tumors [cases (%)]

PD-1 expression on CD8(+) T cells [cases (%)]

Primary tumors

Metastatic lymph nodes

Tumor-free lymph nodes

Low

High

P

Negative

Positive

P

Negative

Positive

P

Negative

Positive

P

Total

119

46

73

 

74

45

 

72

47

 

106

13

 

Sex

   

0.263

  

0.155

  

0.434

  

0.982

 Male

78

33 (42.3)

45 (57.7)

 

45 (57.7)

33 (42.9)

 

45 (57.7)

33 (42.3)

 

69 (88.5)

9 (11.5)

 

 Female

41

13 (31.7)

28 (68.3)

 

29 (70.7)

12 (29.3)

 

27 (65.9)

14 (34.1)

 

37 (90.2)

4 (9.8)

 

Age (years)

   

0.631

  

0.940

  

0.852

  

0.934

 <55

55

20 (36.4)

35 (63.6)

 

34 (61.8)

21 (38.2)

 

34 (61.8)

21 (38.2)

 

49 (89.1)

6 (10.9)

 

 ≥55

64

26 (40.6)

38 (59.4)

 

40 (62.5)

24 (37.5)

 

38 (59.4)

26 (40.6)

 

57 (89.1)

7 (10.9)

 

Tumor location

   

0.782

  

0.464

  

0.552

  

0.648

 Cardia

49

19 (38.8)

30 (61.2)

 

32 (65.3)

17 (34.7)

 

30 (61.2)

19 (38.8)

 

43 (87.8)

6 (12.2)

 

 Body

20

9 (45.0)

11 (55.0)

 

10 (50.0)

10 (50.0)

 

10 (50.0)

10 (50.0)

 

17 (85.0)

3 (15.0)

 

 Antrum

50

18 (36.0)

32 (64.0)

 

32 (64.0)

18 (36.0)

 

32 (64.0)

18 (36.0)

 

46 (92.0)

4 (8.0)

 

Cell differentiation

   

0.660

  

0.981

  

0.799

  

0.906

 Well to moderate

21

9 (42.9)

12 (57.1)

 

13 (61.9)

8 (38.1)

 

12 (57.1)

9 (42.9)

 

20 (95.2)

1 (4.8)

 

 Poor (including Signet ring cell)

98

37 (37.8)

61 (62.2)

 

61 (62.2)

37 (37.8)

 

60 (61.2)

38 (38.8)

 

86 (87.8)

12(12.2)

 

Lauren classification

   

0.011

  

0.103

  

0.061

  

0.239

 Intestinal

60

30 (50.0)

30 (50.0)

 

33 (55.0)

27 (45.0)

 

31 (51.7)

29 (48.3)

 

51 (85.0)

9 (15.0)

 

 Diffuse and mixed

59

16 (27.1)

43 (72.9)

 

41 (69.5)

18 (30.5)

 

41 (69.5)

18 (30.5)

 

55 (93.2)

4 (6.8)

 

Vascular invasion

   

0.302

  

0.114

  

0.454

  

0.572

 Yes

55

24 (43.6)

31 (56.4)

 

30 (54.5)

25 (45.5)

 

41 (64.1)

23 (35.9)

 

58 (90.6)

6 (9.4)

 

 No

64

22 (34.4)

42 (65.6)

 

44 (68.8)

20 (31.3)

 

31 (56.4)

24 (43.6)

 

48 (87.3)

7 (12.7)

 

Neural invasion

   

0.488

  

0.457

  

0.433

  

0.951

 Yes

77

28 (36.4)

49 (63.6)

 

46 (59.7)

31 (40.3)

 

23 (54.8)

19 (45.2)

 

38 (90.5)

4 (9.5)

 

 No

42

18 (42.9)

24 (57.1)

 

28 (66.7)

14 (33.3)

 

49 (53.6)

28 (36.4)

 

68 (88.3)

9 (11.7)

 

Clinical stage

   

0.018

  

0.113

  

0.122

  

0.357

 II–IIIA

12

1 (8.3)

11 (91.7)

 

10 (83.3)

2 (16.7)

 

10 (83.3)

2 (16.7)

 

11 (91.7)

1 (8.3)

 

 IIIB–IIIC

107

45 (42.1)

62 (57.9)

 

64 (59.8)

43 (40.2)

 

62 (57.9)

45 (42.1)

 

95 (88.8)

12 (11.2)